je.st
news
Tag: immunotherapy
Merck Announces FDA Acceptance of Biologics License Application for Investigational Ragweed Pollen Sublingual Allergy Immunotherapy Tablet
2013-05-08 14:30:00| Merck.com - Research & Development News
Dateline City: WHITEHOUSE STATION, N.J. WHITEHOUSE STATION, N.J.--(BUSINESS WIRE)--Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced that the Biologics License Application (BLA) for its investigational ragweed pollen (Ambrosia artemisiifolia) sublingual allergy immunotherapy tablet has been accepted for review by the U.S. Food and Drug Administration (FDA). On March 27, Merck announced that the FDA had also accepted the BLA for its investigational Timothy grass pollen (Phleum pratense) sublingual allergy immunotherapy tablet. Language: English Contact HTML: MerckMedia:Pam Eisele, 908-423-5042Robert Consalvo, 908-423-6595orInvestor:Justin Holko, 908-423-5088 Ticker Slug: Ticker: MRK Exchange: NYSE read more
Tags: application
license
acceptance
announces
Merck Announces FDA Acceptance of Biologics License Application for Investigational Grass Pollen Allergy Immunotherapy Tablet
2013-03-27 13:00:00| Merck.com - Research & Development News
Dateline City: WHITEHOUSE STATION, N.J. WHITEHOUSE STATION, N.J.--(BUSINESS WIRE)--Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced that the Biologics License Application (BLA) for its investigational Timothy grass pollen (Phleum pratense) allergy immunotherapy tablet (AIT) has been accepted for review by the U.S. Food and Drug Administration (FDA). In March, the company also submitted a BLA to the FDA for its investigational ragweed pollen (Ambrosia artemisiifolia) AIT. Language: English Contact HTML: MerckMedia:Pam Eisele, (908) 423-5042Tracy Ogden, (267) 305-2301orInvestors:Justin Holko, (908) 423-5088 Ticker Slug: Ticker: MRK Exchange: NYSE read more
Tags: application
license
acceptance
grass
Merck to Present New Data Analyses of its Investigational Ragweed Pollen and Grass Pollen Allergy Immunotherapy Tablets
2013-02-22 14:30:00| Merck.com - Research & Development News
Dateline City: WHITEHOUSE STATION, N.J. WHITEHOUSE STATION, N.J.--(BUSINESS WIRE)--Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced that researchers will present new data analyses of the safety and efficacy of the companys investigational allergy immunotherapy tablets (AITs) for ragweed pollen (Ambrosia artemisiifolia) and grass pollen (Phleum pratense) at the 2013 American Academy of Allergy, Asthma & Immunology (AAAAI) Annual Meeting. The meeting will be held in San Antonio from February 22-26. Language: English Contact HTML: MerckMedia:Pam Eisele, 908-423-5042orLesley Brown, 267-305-3545orInvestor:Carol Ferguson, 908-423-4465orJustin Holko, 908-423-5088 Ticker Slug: Ticker: MRK Exchange: NYSE read more
Tags: data
present
analyses
grass
Apeiron Closes Regional License Agreement for Antibody-based Immunotherapy:
2013-01-18 16:57:27| Agriculture - Topix.net
Paladin Labs Inc. , one of Canada's leading specialty pharmaceutical companies, entered into an exclusive licensing agreement with Apeiron, under the terms of which Paladin receives the exclusive rights to market and sell APN311 in Canada and Sub-Saharan Africa .
Tags: agreement
license
regional
closes